Transplant Diagnostics Market is poised to register a CAGR of 7.8% during the forecast period (2022-2027).
COVID-19 has impacted the market significantly during the pandemic. According to the study published in Current Transplantation Reports, titled 'Diagnostic Testing of COVID-19 in Solid Organ Transplantation: Current Clinical Application and Future Strategies' in October 2020, multiple elements of solid organ transplantation have been impacted by the COVID-19 pandemic, including donor and recipient appropriateness, as well as infection and transmission prevention following transplantation. During the COVID-19 pandemic, growing knowledge about the diagnostic fidelity and transmissibility of SARS-CoV-2 in immunocompromised patients will continue to guide best practices for solid organ transplantation. Owing to the challenges associated with organ transplantation, the market might have been negatively impacted during the pandemic.
Transplantation is one of the preferred treatment options for many patients suffering from end-stage renal disease and undergoing chronic dialysis therapy. Additionally, transplantation is a viable option considered in cases associated with heart, liver, and bone marrow. In many of the liver associated transplantation, there is significant relation with kidney dysfunction, which includes end-stage renal disorders.
Rising donation of organs is one of the biggest contributors for the growth of the market studied. According to the data published by the Association of Organ Procurement Organizations (AOPO) in January 2021, more than 12,500 people donated one or more organs in 2020, up 6% from the previous year. The number of organs donated from dead donors increased to over 36,500 in 2020, an increase of almost 2% year over year. For the seventh year in a running, these retrieved organs saved more than 33,000 lives, exceeding the previous year's totals. There were also notable increases in Donation after Circulatory Death (DCD) contributions, which totaled more over 3,000 donors, up 18% year over year. The rise in organ donation will lead to increased transplant diagnostic testing, driving the market growth.
In the case of heart transplants, there is significant attention given to diagnostics associated with pulmonary function and overall health. In the past decade, the diagnostics have improved significantly with companies committed to developing better HLA typing technologies, antibody monitoring, instrument, and software. This is gradually being used for diagnostics during transplantation across different organs of the body.
Along with technological advancements, many transplant procedures are being performed by the multispeciality hospitals in the developed markets, as well as growing funding opportunities provided by the government and private collaborations. The diagnosis in transplants is done at the donor's and patient's end, to analyze the infection level inside an organ. Moreover, many key players are launching there products in the market, this is further expected to drive the market growth further. For instance, in September 2021, Thermo Fisher Scientific has included two new additions to their transplant diagnostics portfolio during the American Society for Histocompatibility and Immunogenetics (ASHI) annual conference.
However, some of the limitations include the high cost of transplants, irregular insurance, reimbursement policies, and social and ethical issues related to organ transplants. suc h factors may hinder the growth of the market over the forecast period.
The Solid organ transplant segment is expected to hold a major share over the forecast period. Solid-organ transplantation, which started as an experimental approach in the 20th century, is now considered a well-established and practical definitive treatment option for patients suffering from end-stage organ dysfunction. The majority of transplants are done for kidneys, followed by the liver.
According to the Health Resources & Services Administration in February 2022, there are over 106,000 people on the national transplant waiting list for solid organ transplantation in the United States. The percentage of people waiting for solid organ transplant include Kidney (83%), liver (11%), Pancreas (1%), Heart (3%, Lung (%), and Others (2%). The rise in demand for solid organs will lead to increased testing for this segment, thereby expected to drive the growth of this segment over the forecast period.
In addition, the rising launch of organ transplant tests will also drive the growth of this segment due to the rise in the adoption of these tests. For instance, in September 2021, Natera Inc one of the key players in transforming care through genetic and cell-free DNA (cfDNA) testing, thas launched Prospera with Quantification, the cfDNA test for kidney rejection.
Moreover, rising funding for solid organ transplantation will further contribute the growth of the market studied over the forecast period. For instance, according to the National Institutes of Health (NIH) in June 2021, the funding for organ transplant research in 2018, 2019 and 2020 were USD 184 million, USD 191 million, and USD 208 million respectively. The rise in funding for solid organ transplant research will drive the growth of this segment further due to the rise in adoption of transplant diagnositics in the research.
Therefore, owing to the above mentioned factors, this segment growth is expected to drive over the forecast period.
North America is expected to hold a major share in the transplant diagnostics market and expected to continue same pace over the forecast period.
Countries, like the United States and Canada, are well-equipped with the funded organizations, infrastructure, and government participation in raising funds and awareness, to promote transplantation of organs for patients. For instance, according to the National Institute of Health in June 2021, the fundings for the research in transplantation were USD 650 million, USD 733 million and USD 721 million in 2018, 2019 and 2020 respectively. The rise in funding in the transplantaion research will therefore lead to increased utilization of transplant diagnostics, drivie the growth of the market in this region.
In addition, according to the Organ Donation Statistics published in February 2022, more than 40,000 organ transplantations have been taken place in the United States in 2021. The rise in transplantations will therefore drive the growth of this market over the forecast period.
Rising initiatives from the key market players is expected to contribute the market growth further.These companies are advanced in marketing new products for faster diagnostics of diseases, before and after the transplants, which are well accepted by the private organizations and governments of the United States and Canada. For instance, in March 2022, NephroSant, a biotechnology firm devoted to speeding the assessment of early kidney damagehas recruited first patient in the Evaluation of QSant for Underlying Allograft Rejection (AQUA) study. Up to 2,000 people will be enrolled and observed for 24 months, during which time QSant testing and standard-of-care diagnostics will be used to look for evidence of acute rejection. This type of trials will further boost the market growth of transplant diagnostics in North America due to greater adoption of transplant diagnostic test.
In addition, according to the news published in February 2022, a new first-of-its-kind Canadian study has identified a means to create "universal" organs that may be utilised in any transplant recipient, regardless of blood type. The advancements in the research in organ transplant in Canada will lead to increased adoption of tranplant diagnostics for testing, thereby driving the market growth.
With a large section of the population across the world approach these two nations for better healthcare facilities, the region is expected to be very lucrative for growth and expected to hold a significant share in the market studed over the forecast period.
The market for transplant diagnostics is moderately competitive. The technological advancements, in terms of reagents effectiveness, affordability, clinicians' decision making and raising awareness, and proper organ preservation facilities, are some of the present-day opportunities and challenges that the companies are expected to overcome, during the forecast period. Some of the major companies expanding in the transplant diagnostics market include Abbott Laboratories, Biomérieux SA, F Hoffmann La Roche AG, Qiagen NV, and Thermo Fisher Scientific Inc., among others.
This product will be delivered within 2 business days.
COVID-19 has impacted the market significantly during the pandemic. According to the study published in Current Transplantation Reports, titled 'Diagnostic Testing of COVID-19 in Solid Organ Transplantation: Current Clinical Application and Future Strategies' in October 2020, multiple elements of solid organ transplantation have been impacted by the COVID-19 pandemic, including donor and recipient appropriateness, as well as infection and transmission prevention following transplantation. During the COVID-19 pandemic, growing knowledge about the diagnostic fidelity and transmissibility of SARS-CoV-2 in immunocompromised patients will continue to guide best practices for solid organ transplantation. Owing to the challenges associated with organ transplantation, the market might have been negatively impacted during the pandemic.
Transplantation is one of the preferred treatment options for many patients suffering from end-stage renal disease and undergoing chronic dialysis therapy. Additionally, transplantation is a viable option considered in cases associated with heart, liver, and bone marrow. In many of the liver associated transplantation, there is significant relation with kidney dysfunction, which includes end-stage renal disorders.
Rising donation of organs is one of the biggest contributors for the growth of the market studied. According to the data published by the Association of Organ Procurement Organizations (AOPO) in January 2021, more than 12,500 people donated one or more organs in 2020, up 6% from the previous year. The number of organs donated from dead donors increased to over 36,500 in 2020, an increase of almost 2% year over year. For the seventh year in a running, these retrieved organs saved more than 33,000 lives, exceeding the previous year's totals. There were also notable increases in Donation after Circulatory Death (DCD) contributions, which totaled more over 3,000 donors, up 18% year over year. The rise in organ donation will lead to increased transplant diagnostic testing, driving the market growth.
In the case of heart transplants, there is significant attention given to diagnostics associated with pulmonary function and overall health. In the past decade, the diagnostics have improved significantly with companies committed to developing better HLA typing technologies, antibody monitoring, instrument, and software. This is gradually being used for diagnostics during transplantation across different organs of the body.
Along with technological advancements, many transplant procedures are being performed by the multispeciality hospitals in the developed markets, as well as growing funding opportunities provided by the government and private collaborations. The diagnosis in transplants is done at the donor's and patient's end, to analyze the infection level inside an organ. Moreover, many key players are launching there products in the market, this is further expected to drive the market growth further. For instance, in September 2021, Thermo Fisher Scientific has included two new additions to their transplant diagnostics portfolio during the American Society for Histocompatibility and Immunogenetics (ASHI) annual conference.
However, some of the limitations include the high cost of transplants, irregular insurance, reimbursement policies, and social and ethical issues related to organ transplants. suc h factors may hinder the growth of the market over the forecast period.
Key Market Trends
Solid Organ Transplant Segment is Expected to Hold a Major Share over the Forecast Period
The Solid organ transplant segment is expected to hold a major share over the forecast period. Solid-organ transplantation, which started as an experimental approach in the 20th century, is now considered a well-established and practical definitive treatment option for patients suffering from end-stage organ dysfunction. The majority of transplants are done for kidneys, followed by the liver.
According to the Health Resources & Services Administration in February 2022, there are over 106,000 people on the national transplant waiting list for solid organ transplantation in the United States. The percentage of people waiting for solid organ transplant include Kidney (83%), liver (11%), Pancreas (1%), Heart (3%, Lung (%), and Others (2%). The rise in demand for solid organs will lead to increased testing for this segment, thereby expected to drive the growth of this segment over the forecast period.
In addition, the rising launch of organ transplant tests will also drive the growth of this segment due to the rise in the adoption of these tests. For instance, in September 2021, Natera Inc one of the key players in transforming care through genetic and cell-free DNA (cfDNA) testing, thas launched Prospera with Quantification, the cfDNA test for kidney rejection.
Moreover, rising funding for solid organ transplantation will further contribute the growth of the market studied over the forecast period. For instance, according to the National Institutes of Health (NIH) in June 2021, the funding for organ transplant research in 2018, 2019 and 2020 were USD 184 million, USD 191 million, and USD 208 million respectively. The rise in funding for solid organ transplant research will drive the growth of this segment further due to the rise in adoption of transplant diagnositics in the research.
Therefore, owing to the above mentioned factors, this segment growth is expected to drive over the forecast period.
North America is Expected to Hold a Major Share and Expected to Show the same Pace over the Forecast Period
North America is expected to hold a major share in the transplant diagnostics market and expected to continue same pace over the forecast period.
Countries, like the United States and Canada, are well-equipped with the funded organizations, infrastructure, and government participation in raising funds and awareness, to promote transplantation of organs for patients. For instance, according to the National Institute of Health in June 2021, the fundings for the research in transplantation were USD 650 million, USD 733 million and USD 721 million in 2018, 2019 and 2020 respectively. The rise in funding in the transplantaion research will therefore lead to increased utilization of transplant diagnostics, drivie the growth of the market in this region.
In addition, according to the Organ Donation Statistics published in February 2022, more than 40,000 organ transplantations have been taken place in the United States in 2021. The rise in transplantations will therefore drive the growth of this market over the forecast period.
Rising initiatives from the key market players is expected to contribute the market growth further.These companies are advanced in marketing new products for faster diagnostics of diseases, before and after the transplants, which are well accepted by the private organizations and governments of the United States and Canada. For instance, in March 2022, NephroSant, a biotechnology firm devoted to speeding the assessment of early kidney damagehas recruited first patient in the Evaluation of QSant for Underlying Allograft Rejection (AQUA) study. Up to 2,000 people will be enrolled and observed for 24 months, during which time QSant testing and standard-of-care diagnostics will be used to look for evidence of acute rejection. This type of trials will further boost the market growth of transplant diagnostics in North America due to greater adoption of transplant diagnostic test.
In addition, according to the news published in February 2022, a new first-of-its-kind Canadian study has identified a means to create "universal" organs that may be utilised in any transplant recipient, regardless of blood type. The advancements in the research in organ transplant in Canada will lead to increased adoption of tranplant diagnostics for testing, thereby driving the market growth.
With a large section of the population across the world approach these two nations for better healthcare facilities, the region is expected to be very lucrative for growth and expected to hold a significant share in the market studed over the forecast period.
Competitive Landscape
The market for transplant diagnostics is moderately competitive. The technological advancements, in terms of reagents effectiveness, affordability, clinicians' decision making and raising awareness, and proper organ preservation facilities, are some of the present-day opportunities and challenges that the companies are expected to overcome, during the forecast period. Some of the major companies expanding in the transplant diagnostics market include Abbott Laboratories, Biomérieux SA, F Hoffmann La Roche AG, Qiagen NV, and Thermo Fisher Scientific Inc., among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Becton, Dickinson and Company
- Biomérieux SA
- Bio-Rad Laboratories Inc.
- CareDx
- F Hoffman-La Roche AG
- Hologic Inc.
- Illumina Inc.
- Qiagen NV
- Thermo Fisher Scientific Inc.
- Immucor, Inc.
- Omixon Ltd.
- GenDx
- BioGenuix
